Company Overview: Cytori

Industry News

29 Nov

Cytori Closes Rights Offering for Gross Proceeds of $10 Million

SAN DIEGO, Nov. 28, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (“Cytori”) (CYTX) announced today the closing of its rights offering (the “Rights Offering”) to subscribe for units at a subscription price of $1,000 per unit. Pursuant to the Rights Offering, Cytori sold an aggregate of 10,000 units consisting of...

Read more

16 Nov

Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS

Pharmacokinetic Bioequivalence Shown for Cytori’s ATI-0918 Liposomal Formulation of Doxorubicin Hydrochloride, Results Presented at the 2017 American Association of Pharmaceutical Scientists Annual Meeting SAN DIEGO, Nov. 16, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced the results of its pharmacokinetic bioequivalence trial of ATI-0918 (test product)...

Read more

13 Nov

Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis

SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or “the Company”) today announced a new investigator initiated U.S. clinical trial for hip osteonecrosis. Details of the trial can be assessed at https://clinicaltrials.gov/ct2/show/NCT03269409. Cytori Cell Therapy™ technology is approved for use in many countries around the world and...

Read more

7 Nov

STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress

SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or “the Company”) announced today that its U.S. STAR clinical trial assessing the safety and efficacy  of Habeo™ Cell Therapy for hand dysfunction due to systemic scleroderma (SSc) has been accepted for presentation at the 5th Systemic Sclerosis World...

Read more

6 Nov

Cytori to Webcast Third Quarter Financial Results on November 9

SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its third quarter financial results and business update on Thursday, November 9, 2017 at 5:30 PM Eastern Time. The dial-in information is as follows: Dial-In Number: +1.877.402.3914 Conference ID: 5289756 Prior...

Read more

2 Nov

Cytori to Webcast Third Quarter Financial Results on November 9

SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its third quarter financial results and business update on Thursday, November 9, 2017 at 5:30 PM Eastern Time. The dial-in information is as follows: Dial-In Number: +1.877.402.3914 Conference ID: 5289756 Prior...

Read more

24 Jul

Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma

Statistical significance not achieved in primary or secondary efficacy endpoints Clinically meaningful efficacy trends observed in primary and secondary endpoints in pre-specified diffuse cutaneous scleroderma subgroup No significant safety related issues Conference call scheduled for 8:30am EDT  SAN DIEGO, July 24, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX)...

Read more

6 Jul

Cytori Receives Key Cell Therapy Patent for Scleroderma

Strengthens Global Scleroderma Intellectual Property Portfolio Extends E.U. protection through 2034 SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) —  Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) announced today the issuance of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has 107...

Read more

Page 1 of 712345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address